INDIA OUTSOURCING COMPANY

DESCRIPTION
COMPANY PROFILE – TABLETS (INDIA) LTD

Tablet (India) Limited (TIL) is a fully integrated medium-sized pharmaceutical company, formed in 1938—is part of the Jhaver Conglomerate with an annual turnover of about $150 million. In the Indian pharma industry. TIL ranks among top pharmaceutical companies with annual turnover of around $25 million with a consistent annual growth of 30% against the industry growth of 10%. During the 25 years history, TIL has built up a reputation in the country as a leader in parentral and enteral nutrition, critical care support specialising in Amino Acid formulations and Pre & Probiotics. TIL has also established its leadership role in therapeutic segments extending to Metabolic disorders, Gastrointestinal ailments, Gynecological conditons, Post surgical management and Respiratory ailments etc.

TIL’s operations include Development, In-Licensing and Marketing of Pharmaceutical and Nutraceutical products. With a total of 950+ employees, all fields of pharmaceutical business are covered: - Pharmaceutical development - Manufacturing - Quality control - Clinical research - Regulatory Affairs - Marketing - Sales forces. TIL also has a separate Division looking at toll manufacturing / contract manufacturing activities under its portfolio and is scouting for many more.

As part of its In-Licensing operations, TIL has a 30+ years association with ROUSSEL MORISHITA and AJINOMOTO Corporation, a world leader in Amino Acids. Other In-Licensing alliances that are, since 6 years with KOTOBUKI Pharmaceuticals and for 5 years with TOA Pharmaceuticals in Japan and for 13 years with ROCHE in the Europe. The recent prestegious alliances that include are Nikken Pharmaceuticals, Walkamoto of Japan and Urex Biotech, Canada / Chr. Hansen of Denmark for manufacture and marketing of new generation Probiotics. These are furnished as below:

Name of the Japanese company Period of association / licensing arrangement
Ajinomoto Pharma Company Ltd, Tokyo Since 34 years
TOA Pharmaceutical Company Ltd, Tokyo Since 5 years
Nikken Chemicals, Tokyo Since 3 years
Kotobuki Pharmaceutical Company Ltd, Nagano Since 6 years


TIL has GMP regulated manufacturing facilities that are approved by WHO and accredited as an ISO 9001 facility. It is also certified by Societe’ Generale Da Surveillance, S.A. Geneva. In order to maintain and enhance its competitiveness at the national and international level TIL is committed to invest extensively on product quality, infrastructure, modernization and expansion.

TIL is equipped with a highly qualified, experienced team of scientists and pharmaceutical physicians dedicated to pre-clinical and clinical research and development in areas of critical Nutrition, Nutraceuticals and Pre & Probiotics.

TIL is currently manufacturing various types of products in dosage form of tablets, capsules, soft gel, injectible, powder etc., in their multi-location manufacturing facilities. These manufacturing facilities are used for both TIL’s own requirements and also as a contract / toll manufacturing facilities for other prestigious companies. Some of our toll manufacturing clients include Baxter, Ranbaxy, ICI (UK) etc., With our strength in production and development, we are in search for toll manufacturing / contract manufacturing arrangements on a long-term. It is, therefore, our constant endevour to invite like-minded partnership for business development

SKILLS
TIL has built up a reputation in the country as a leader in parentral and enteral nutrition, critical care support specialising in Amino Acid formulations and Pre & Probiotics. TIL has also established its leadership role in therapeutic segments extending to Metabolic disorders, Gastrointestinal ailments, Gynecological conditons, Post surgical management and Respiratory ailments etc

TERMS
Prices: Depends upon the product

Payment Terms: Irrevocabale L/C at sight

LOCATION India - Chennai, Tamil Nadu EMPLOYEES 100-499 YEARS IN BUSINESS 11+ years CONTACT INFORMATION Register or Login to view the outsourcing service provider contact information.